Mariusz Kuśmierczyk

Mariusz Kuśmierczyk

Auto-generated profile, based on publicly available information

Mariusz Kuśmierczyk

Department of Cardiac Surgery, Medical University of Warsaw , st. Banacha 1a, 02-097 Warsaw , Poland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Journal of Thoracic Disease
Verified
Journal Article
Open access
KBKrzysztof Bartuś
Krzysztof Bartuś
RLRadosław Litwinowicz
Radosław Litwinowicz
ABAgata Bilewska
Agata Bilewska
MSMaciej Stapor
Maciej Stapor
MBMaciej Bochenek
Maciej Bochenek
MKMariusz Kusmierczyk
Mariusz Kusmierczyk
The durability of bioprosthetic heart valves is limited by structural valve deterioration (SVD) due to long-term calcification. A novel bioprosthetic tissue (RESILIATM) has been developed which, in preclinical studies, has shown reduced calcification. The purpose of this study was to evaluate the intermediate-term clinical outcomes and hemodynamic performance of this tissue. A prospective, single-arm, observational trial was conducted in patients who required surgical aortic valve replacement (AVR). Between July 2011 and February 2013, 133 patients were implanted at two sites in Poland. Hemodynamic performance and clinical outcomes were assessed annually through 4 years of follow-up. All safety events were adjudicated by an independent Clinical Events Committee, and echocardiographic data were evaluated by a core laboratory. Patients were 65.3±13.5 years old and 26% were ≤60 years old. The average follow-up was 3.8±1.1 (median: 4.1; IQR, 4.0-4.3) years. Early (≤30 day) and late (>30 day) all-cause mortality rates were 2.3% (n=3) and 3.2% late patient-years (n=16), respectively. There were no cases of early or late SVD. There was one early case of major paravalvular leak (0.8%), and no late cases. At 4 years, the mean gradient was 14.5±7.4 mmHg and the effective orifice area was 1.6±0.4 cm2, both markedly improved from baseline. At 4 years, the New York Heart Association functional class had improved from baseline in 54.5% of patients. The aortic bioprosthesis with novel RESILIATM tissue demonstrated excellent hemodynamic performance and safety outcomes over 4 years. Longer follow-up will be important to confirm the durability of this bioprosthesis.

1 February 2020 in Shock
Verified
Journal Article
Open access
PDPiotr Duchnowski
Piotr Duchnowski
THTomasz Hryniewiecki
Tomasz Hryniewiecki
MKMariusz Kuśmierczyk
Mariusz Kuśmierczyk
PSPiotr Szymański
Piotr Szymański
Background: Cardiogenic shock is a very serious postoperative complication in patients undergoing heart valve surgery. Mechanical circulatory support is a recognized method of treating patients with this complication. The aim of the presented study was to assess the usefulness of selected biomarkers in predicting the occurrence of postoperative cardiogenic shock requiring mechanical circulatory support. Methods: This prospective study was conducted on a group of 712 patients undergoing heart valve surgery. The primary end-point at the intrahospital follow-up was postoperative cardiogenic shock requiring mechanical circulatory support. Results: The postoperative cardiogenic shock requiring mechanical circulatory support occurred in 20 patients. At multivariate analysis high-sensitivity Troponin T measured immediately after surgery (OR 1.006; 95% CI 1.002–1.013; P 0.009) remained independent predictor of the primary end point. Conclusions: The postoperative hs-TnT can be used to predict a postoperative cardiogenic shock requiring mechanical circulatory support.

29 December 2021 in Polish Heart Journal
Verified
Journal Article
Open access
PDF file
ATAgnieszka Tycinska
Agnieszka Tycinska
MGMarek Grygier
Marek Grygier
JBJan Biegus
Jan Biegus
TCTomasz Czarnik
Tomasz Czarnik
MDMaciej Dabrowski
Maciej Dabrowski
RZRobert Zymliński
Robert Zymliński
Mechanical circulatory support (MCS) methods are used in patients with both acute and chronic heart failure, who have exhausted other options for pharmacological or surgical treatments. The purpose of their use is to support, partially or completely, the failed ventricles and ensure adequate organ perfusion, which allows patients to restore full cardiovascular capacity, prolonging their life and effectively improving its quality. The three most popular devices include an intra-aortic balloon pump (IABP), percutaneous assist devices (including Impella, TandemHeart), and venoarterial extracorporeal membrane oxygenation (VA-ECMO). A multidisciplinary approach with the special participation of the Heart Team is required to determine the proper MCS strategy, the choice of the supporting method, and the time of its use. The studies published so far do not allow us to determine which MCS method is the safest and the most effective. Thus, the site experience and accessibility of the method seem to matter most today. MCS finds particular application in patients with acute coronary syndromes complicated by refractory cardiogenic shock, as well as in patients with acute heart failure of the high potential for reversibility. It can also serve as a backup for percutaneous coronary interventions of high risk (complex and high-risk indicated percutaneous coronary intervention [PCI], complex and high-risk indicated PCI [CHIP]). The use of appropriate supportive drugs, precise hemodynamic and echocardiographic monitoring, as well as optimal non-invasive or mechanical ventilation, are extremely important in the management of a patient with MCS. The most serious complications of MCS include bleeding, thromboembolic events, as well as infections, and hemolysis.

1 January 2016 in Polish Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
IMIlona Michalowska
Ilona Michalowska
JĆJarosław Ćwikła
Jarosław Ćwikła
APAleksander Prejbisz
Aleksander Prejbisz
PKPaweł Kwiatek
Paweł Kwiatek
MSMałgorzata Szperl
Małgorzata Szperl
MPMariola Pęczkowska
Mariola Pęczkowska
Introduction : Paragangliomas (PGLs) related to hereditary syndromes are rare mediastinal tumors. Paragangliomas are caused by mutations in genes encoding subunits of succinate dehydrogenase enzyme (SDH). Aim: To evaluate clinical, anatomical and functional characteristics of mediastinal...

10 April 2018 in Polish Heart Journal
Verified
Journal Article
Closed access
PDF file
PLPaweł Litwiński
Paweł Litwiński
PKPiotr Kołsut
Piotr Kołsut
TSTadeusz Sitko
Tadeusz Sitko
Tomasz ZielińskiTomasz Zieliński
Tomasz Zieliński
PHPiotr Hoffman
Piotr Hoffman
MKMariusz Kuśmierczyk
Mariusz Kuśmierczyk
Background and aim: This retrospective analysis of patients with severe tricuspid valve disease, who underwent tricuspid valve replacement (TVR) for either tricuspid regurgitation or stenosis, has been designed to determine the factors that predict poor hospital and long-term survival. Methods: The study population comprised 86 patients, 65 women and 21 men, who underwent TVR with or without con-comitant surgical procedures between 2000 and 2010 at our institution. Patients with Ebstein’s or other complex congenital anomalies were excluded from the study. Results: Average age at operation was 58.5 ± 12.5 (range 16–78) years. Fifty (58.1%) patients had undergone previous cardiac surgery. Forty-two patients were in New York Heart Association (NYHA) class III functional capacity, and 18 were in class IV. Symptoms of right heart failure (HF) were present in 66 patients, of whom 19 had ascites. Bioprosthetic tricuspid valves were implanted in 84 patients and mechanical prostheses in two. The choice to proceed to TVR instead of repair was individualised and based on the surgeon’s preference. In-hospital mortality was 18 (20.9%) patients, caused mainly by multi-organ and HF, and was significantly related to NYHA class and symptoms of right HF before surgery, with no mortality in patients with NYHA class I and II, 19% mortality with NYHA class III, and 55.6% mortality with NYHA class IV. Eighteen (20.9%) patients died during postoperative follow-up. The main risk factors associated with perioperative mortality were: the presence of severe symptoms at the time of surgery, low preoperative haematocrit, postoperative complications, postoperative ventilation time longer than 72 h, and renal failure requiring dialysis. Elevated pulmonary artery pressure, preoperative symptoms of right HF, and low haematocrit unfavourably affected the long-term results. Conclusions: Many earlier studies reported high mortality and morbidity after TVR in both early and late postoperative peri-ods. Our main finding is that good outcomes for TVR are achievable in properly selected patients. Sixty of 86 patients in our group had preoperative NYHA functional class III and IV, which suggests that surgical timing was late in many patients. Based on our observations, we propose that surgical correction of severe tricuspid valve disease should be considered before the development of advanced HF, when patients are asymptomatic or only oligosymptomatic. Background and aim: This retrospective analysis of patients with severe tricuspid valve disease, who underwent tricuspid valve replacement (TVR) for either tricuspid regurgitation or stenosis, has been designed to determine the factors that predict poor hospital and long-term survival. Methods: The study population comprised 86 patients, 65 women and 21 men, who underwent TVR with or without con-comitant surgical procedures between 2000 and 2010 at our institution. Patients with Ebstein’s or other complex congenital anomalies were excluded from the study. Results: Average age at operation was 58.5 ± 12.5 (range 16–78) years. Fifty (58.1%) patients had undergone previous cardiac surgery. Forty-two patients were in New York Heart Association (NYHA) class III functional capacity, and 18 were in class IV. Symptoms of right heart failure (HF) were present in 66 patients, of whom 19 had ascites. Bioprosthetic tricuspid valves were implanted in 84 patients and mechanical prostheses in two. The choice to proceed to TVR instead of repair was individualised and based on the surgeon’s preference. In-hospital mortality was 18 (20.9%) patients, caused mainly by multi-organ and HF, and was significantly related to NYHA class and symptoms of right HF before surgery, with no mortality in patients with NYHA class I and II, 19% mortality with NYHA class III, and 55.6% mortality with NYHA class IV. Eighteen (20.9%) patients died during postoperative follow-up. The main risk factors associated with perioperative mortality were: the presence of severe symptoms at the time of surgery, low preoperative haematocrit, postoperative complications, postoperative ventilation time longer than 72 h, and renal failure requiring dialysis. Elevated pulmonary artery pressure, preoperative symptoms of right HF, and low haematocrit unfavourably affected the long-term results. Conclusions: Many earlier studies reported high mortality and morbidity after TVR in both early and late postoperative peri-ods. Our main finding is that good outcomes for TVR are achievable in properly selected patients. Sixty of 86 patients in our group had preoperative NYHA functional class III and IV, which suggests that surgical timing was late in many patients. Based on our observations, we propose that surgical correction of severe tricuspid valve disease should be considered before the development of advanced HF, when patients are asymptomatic or only oligosymptomatic.

1 March 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
MKMichalina Krych
Michalina Krych
KJKamila Janisz
Kamila Janisz
JKJarosław Kuriata
Jarosław Kuriata
MKMariusz Kuśmierczyk
Mariusz Kuśmierczyk
PHPiotr Hoffman
Piotr Hoffman
EBElżbieta Katarzyna Biernacka
Elżbieta Katarzyna Biernacka
Andersen–Tawil syndrome (ATS) is a channelopathy characterized by the triad of symptoms, amongst other ventricular arrhythmias.